Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Apr 2, 2026
Company Deals

Shanghai BDgene Secures Hundreds of Millions in Financing to Advance Dual Gene Therapy Platforms

Fineline Cube Apr 2, 2026
Company Deals

Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases

Fineline Cube Apr 1, 2026
Company Deals

Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition

Fineline Cube Apr 1, 2026
Company Deals

Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform

Fineline Cube Apr 1, 2026
Policy / Regulatory

China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs

Fineline Cube Apr 2, 2026
Company Drug

NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal

Fineline Cube Apr 2, 2026
Company Drug

Sichuan Biokin Receives NMPA Approval for Phase II/III Trials of First-in-Class Bispecific ADC Iza-bren in Prostate and Ovarian Cancers

Fineline Cube Apr 2, 2026
Policy / Regulatory

Give Kids a Chance Act Extends FDA Pediatric Research Authority and PRV Program

Fineline Cube Feb 6, 2026

The US Congress has introduced the Give Kids a Chance Act, legislation aimed at broadening...

Company

Eli Lilly Revenue Surges 45% to $65.2B on Incretin Portfolio Strength

Fineline Cube Feb 5, 2026

Eli Lilly and Company (NYSE: LLY) reported fourth‑quarter 2025 revenue of USD 19.29 billion, up 43% year‑on‑year (YOY),...

Company

Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion

Fineline Cube Feb 5, 2026

Novartis AG (NYSE: NVS) reported full‑year 2025 net sales of USD 54.5 billion, up 8% year‑on‑year (YOY) at...

Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026

Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug...

Company Medical Device

GE HealthCare Revenue Grows 5% to $20.6B on Imaging and Diagnostics Strength

Fineline Cube Feb 5, 2026

GE HealthCare (NASDAQ: GEHC) reported fourth‑quarter 2025 revenue of USD 5.7 billion, up 7.1% year‑on‑year (YOY), bringing full‑year...

Company Deals

MediTrust Mabwell Insurance Ecosystem Partnership

Fineline Cube Feb 5, 2026

Shanghai MediTrust Health Technology Group Co., Ltd. (a subsidiary of Shanghai Pharmaceuticals) announced a comprehensive...

Company Drug

Hanx Biopharma HX111 ADC Begins Phase I Trial for Lymphoma and Solid Tumors

Fineline Cube Feb 5, 2026

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced the initiation of a Phase I clinical...

Company Deals

Pfizer Launches Migraine Management Zone at China Pharmacy

Fineline Cube Feb 5, 2026

Pfizer Inc. (NYSE: PFE) in collaboration with GuoDa Drugstore Co., Ltd. (part of Sinopharm) this week...

Company Drug

Shouyao’s SY-9453 MAT2A Inhibitor Gets NMPA Nod for MTAP-Deleted Tumors

Fineline Cube Feb 5, 2026

Shouyao Holdings (Beijing) Co., Ltd. (SHA: 688197) announced that the National Medical Products Administration (NMPA)...

Company

Innovent Biologics Revenue Surges 45% on Oncology Portfolio Expansion

Fineline Cube Feb 5, 2026

Innovent Biologics, Inc. (HKG: 1801) reported strong financial results for Q4 and full‑year 2025, with total...

Company Drug

Huadong Medicine DR10624 Gets NMPA Nod for Hypertriglyceridemia Study

Fineline Cube Feb 5, 2026

Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary Doer Biologics has received National...

Company Deals

Takeda Ends $128M Kyoto University iPSC Project After Decade of Research

Fineline Cube Feb 5, 2026

Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced the termination of its ten‑year induced pluripotent stem cell (iPSC)...

Hospital Policy / Regulatory

Beijing Online Consultation Pilot Gets NHC Approval for Children’s Care

Fineline Cube Feb 5, 2026

China’s National Health Commission (NHC) has approved the “Standardized Pilot Program for Online Initial Consultations...

Company Drug

AstraZeneca Saphnelo Faces FDA Setback with Complete Response Letter

Fineline Cube Feb 5, 2026

AstraZeneca (AZ, NASDAQ: AZN) announced it has received a Complete Response Letter (CRL) from the U.S....

Company

AbbVie Immunology Portfolio Drives $61.2B Revenue in 2025

Fineline Cube Feb 5, 2026

AbbVie Inc. (NYSE: ABBV) reported fourth‑quarter revenue of USD 16.618 billion, up 9.5% year‑on‑year (YOY), bringing full‑year 2025...

Company Deals Digital

Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System

Fineline Cube Feb 5, 2026

Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its...

Company Deals

Lishan Biopharma Licenses Evogene’s LS-LBP-002 for Global Oncology Development

Fineline Cube Feb 5, 2026

Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel‑based Evogene Ltd. (NASDAQ: EVGN) for...

Company

Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows

Fineline Cube Feb 4, 2026

Pfizer Inc. (NYSE: PFE) reported full‑year 2025 revenue of USD 62.6 billion, representing a 2% operational decline at constant...

Others

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump

Fineline Cube Feb 4, 2026

Merck & Co. (MSD, NYSE: MRK) reported full‑year 2025 revenue of USD 65.5 billion, up 2% year‑on‑year...

Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Fineline Cube Feb 4, 2026

Hualan Biological Engineering Inc. (SHE: 002007) announced that the National Medical Products Administration (NMPA) has...

Posts pagination

1 … 25 26 27 … 645

Recent updates

  • NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal
  • Sichuan Biokin Receives NMPA Approval for Phase II/III Trials of First-in-Class Bispecific ADC Iza-bren in Prostate and Ovarian Cancers
  • Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer
  • China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs
  • Eli Lilly Secures FDA Approval for Foundayo (Orforglipron) in Obesity Treatment, Shipments Begin April 6
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves World’s First Broad-Spectrum Tumor Imaging Agent 99mTc-3PRGD2 from Radio Medicinal

Company Drug

Sichuan Biokin Receives NMPA Approval for Phase II/III Trials of First-in-Class Bispecific ADC Iza-bren in Prostate and Ovarian Cancers

Company Deals Drug

Zai Lab and Amgen Partner to Evaluate ADC-BiTE Combination Therapy for Extensive-Stage Small Cell Lung Cancer

Policy / Regulatory

China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.